Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

'Very Impressive' Survival With Combo in First-Line Prostate Cancer Study



(MedPage Today) — SAN FRANCISCO — The first-line combination of olaparib (Lynparza) plus abiraterone (Zytiga) led to a significant overall survival (OS) advantage for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments